CSIMarket
 
Prevail Therapeutics Inc   (PRVL)
Other Ticker:  
 

Prevail Therapeutics Inc

Business Description


Prevail Therapeutics Inc is a biotechnology company that was founded in 2017 and is headquartered in New York, United States. The company is focused on developing gene therapies for patients with neurodegenerative diseases such as Parkinson*s disease and frontotemporal dementia.

Prevail Therapeutics is committed to developing precision medicines that target the underlying causes of neurodegeneration. Their approach involves using gene therapies to deliver healthy genes or modified genes to patients* cells, with the goal of reversing or slowing down the progression of these diseases.

The company*s research and development efforts are based on the understanding that many neurodegenerative diseases are caused by faulty or mutated genes. Prevail Therapeutics aims to correct these genetic defects by introducing therapeutic genes into the affected cells, thereby restoring normal function.

Prevail Therapeutics has a diverse pipeline of potential gene therapies, each targeting a specific gene mutation associated with neurodegenerative diseases. Their lead product candidate, PR001, is designed to address a genetic mutation associated with Parkinson*s disease. This investigational therapy aims to deliver a functional copy of the gene to affected brain cells, thereby restoring the production of a key enzyme that is deficient in Parkinson*s patients.

In addition to PR001, Prevail Therapeutics is also developing other gene therapies, including PR006 and PR004, targeting different gene mutations associated with Parkinson*s disease and frontotemporal dementia, respectively. The company also has ongoing research programs focused on identifying and targeting other genetic mutations that contribute to the development of neurodegenerative diseases.

Prevail Therapeutics utilizes a multidisciplinary approach to drug development, incorporating various disciplines such as genetics, neuroscience, and bioengineering. They collaborate with leading scientists, clinicians, and researchers to advance their understanding of neurodegenerative diseases and develop innovative therapies.

To support their research and development efforts, Prevail Therapeutics has established strategic partnerships and collaborations with academic institutions, hospitals, and other biotechnology companies. These partnerships allow for the exchange of knowledge, expertise, and resources, facilitating the advancement of their gene therapy programs.

Overall, Prevail Therapeutics is a biotechnology company dedicated to developing gene therapies for patients with neurodegenerative diseases. Their extensive research and development efforts, combined with strategic collaborations, position them well to make significant contributions to the field of precision medicine.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com